» Articles » PMID: 21484087

The P2X1 Receptor and Platelet Function

Overview
Publisher Springer
Date 2011 Apr 13
PMID 21484087
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Extracellular nucleotides are ubiquitous signalling molecules, acting via the P2 class of surface receptors. Platelets express three P2 receptor subtypes, ADP-dependent P2Y1 and P2Y12 G-protein-coupled receptors and the ATP-gated P2X1 non-selective cation channel. Platelet P2X1 receptors can generate significant increases in intracellular Ca(2+), leading to shape change, movement of secretory granules and low levels of α(IIb)β(3) integrin activation. P2X1 can also synergise with several other receptors to amplify signalling and functional events in the platelet. In particular, activation of P2X1 receptors by ATP released from dense granules amplifies the aggregation responses to low levels of the major agonists, collagen and thrombin. In vivo studies using transgenic murine models show that P2X1 receptors amplify localised thrombosis following damage of small arteries and arterioles and also contribute to thromboembolism induced by intravenous co-injection of collagen and adrenaline. In vitro, under flow conditions, P2X1 receptors contribute more to aggregate formation on collagen-coated surfaces as the shear rate is increased, which may explain their greater contribution to localised thrombosis in arterioles compared to venules within in vivo models. Since shear increases substantially near sites of stenosis, anti-P2X1 therapy represents a potential means of reducing thrombotic events at atherosclerotic plaques.

Citing Articles

P2X receptors exhibit at least three modes of allosteric antagonism.

Oken A, Ditter I, Lisi N, Krishnamurthy I, Godsey M, Mansoor S Sci Adv. 2024; 10(40):eado5084.

PMID: 39365862 PMC: 11451537. DOI: 10.1126/sciadv.ado5084.


High-affinity agonism at the P2X receptor is mediated by three residues outside the orthosteric pocket.

Oken A, Lisi N, Krishnamurthy I, McCarthy A, Godsey M, Glasfeld A Nat Commun. 2024; 15(1):6662.

PMID: 39107314 PMC: 11303814. DOI: 10.1038/s41467-024-50771-6.


Is glycoprotein VI involved in contractual negotiations?.

Brysland S, Hearn J, Gardiner E Res Pract Thromb Haemost. 2024; 8(1):102329.

PMID: 38404946 PMC: 10883811. DOI: 10.1016/j.rpth.2024.102329.


Adenosine, Schizophrenia and Cancer: Does the Purinergic System Offer a Pathway to Treatment?.

Hamoud A, Bach K, Kakrecha O, Henkel N, Wu X, McCullumsmith R Int J Mol Sci. 2022; 23(19).

PMID: 36233136 PMC: 9570456. DOI: 10.3390/ijms231911835.


The P2X1 receptor as a therapeutic target.

Bennetts F, Mobbs J, Ventura S, Thal D Purinergic Signal. 2022; 18(4):421-433.

PMID: 35821454 PMC: 9832217. DOI: 10.1007/s11302-022-09880-4.


References
1.
Oury C, Kuijpers M, Toth-Zsamboki E, Bonnefoy A, Danloy S, Vreys I . Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood. 2003; 101(10):3969-76. DOI: 10.1182/blood-2002-10-3215. View

2.
Crittenden J, Bergmeier W, Zhang Y, Piffath C, Liang Y, Wagner D . CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med. 2004; 10(9):982-6. DOI: 10.1038/nm1098. View

3.
Browne L, Jiang L, North R . New structure enlivens interest in P2X receptors. Trends Pharmacol Sci. 2010; 31(5):229-37. PMC: 2954318. DOI: 10.1016/j.tips.2010.02.004. View

4.
Mahaut-Smith M, Sage S, Rink T . Rapid ADP-evoked currents in human platelets recorded with the nystatin permeabilized patch technique. J Biol Chem. 1992; 267(5):3060-5. View

5.
Wen H, Evans R . Regions of the amino terminus of the P2X receptor required for modification by phorbol ester and mGluR1alpha receptors. J Neurochem. 2008; 108(2):331-40. PMC: 2704932. DOI: 10.1111/j.1471-4159.2008.05761.x. View